70 Investor presentation First nine months of 2022 In STEP 8, semaglutide 2.4 mg sh compared to 6.6% with liraglutide STEP 8 observed mean change in body weight 1 Mean baseline body weight: 104.5 kg 0 % change in body weight -5 -10 -15 Sema 2.4 mg Lira 3.0 mg Placebo -20 68 Time since Initiation (Weeks) 1 Observed data for the on-treatment period; *p-value <0.0001 vs lira 3.0 mg; % change in body weight measured as change from b Data shown is the trial product estimand ; Sema: semaglutide; Lira: liraglutide
Download PDF file